Aranesp Takes A Punch; Sales Plummet 25 Percent In Fourth Quarter 2007
This article was originally published in The Pink Sheet Daily
Executive Summary
With ESA safety in the spotlight, Amgen faced its toughest year, CEO Sharer says.
You may also be interested in...
Denosumab Fracture Data Positive In Prostate Cancer Patients
Amgen’s twice-yearly injection still has high bar to pass on fracture risk reduction in postmenopausal women with osteoporosis.
Denosumab Fracture Data Positive In Prostate Cancer Patients
Amgen’s twice-yearly injection still has high bar to pass on fracture risk reduction in postmenopausal women with osteoporosis.
Amgen’s Denosumab Beats Alendronate – Again
New BMD data offer another piece of the osteo puzzle; fracture results still due later this year.